State of New Jersey Common Pension Fund D Raises Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

State of New Jersey Common Pension Fund D grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 123,587 shares of the company’s stock after acquiring an additional 28,600 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Hims & Hers Health were worth $2,276,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Renaissance Technologies LLC boosted its holdings in Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. Farallon Capital Management LLC lifted its position in Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares during the last quarter. M&G Plc purchased a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $8,232,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Hims & Hers Health by 164.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System increased its stake in shares of Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after buying an additional 320,000 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HIMS. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating in a report on Thursday. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $21.21.

Insider Transactions at Hims & Hers Health

In related news, Director Anja Manuel acquired 4,000 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $26.94 per share, with a total value of $107,760.00. Following the completion of the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $107,760. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the sale, the chief executive officer now owns 33,502 shares in the company, valued at $487,789.12. This represents a 84.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 996,961 shares of company stock worth $20,256,416. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Down 24.5 %

HIMS stock opened at $20.85 on Friday. The business has a 50 day moving average of $19.51 and a 200 day moving average of $18.77. The firm has a market cap of $4.48 billion, a PE ratio of 49.34 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $7.40 and a twelve month high of $30.44.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period last year, the company earned ($0.04) earnings per share. The company’s revenue was up 77.1% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.